Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology StudyBusiness Wire • 07/22/26
Billionaire Investor Stanley Druckenmiller's Top 5 Picks: Worth Buying Today?24/7 Wall Street • 07/20/26
Finalized MolDx LCD Includes Expanded Coverage for Natera's Prospera™ PortfolioBusiness Wire • 07/16/26
NTRA's Signatera Gains EU IVDR Certification for Multiple CancersZacks Investment Research • 07/10/26
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal CancerBusiness Wire • 07/06/26
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck CancerZacks Investment Research • 07/01/26
Medical Services Name Tests For Colon Cancer. Natera Stock Hits A High.Investors Business Daily • 06/29/26
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck CancerBusiness Wire • 06/29/26
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in JapanZacks Investment Research • 06/25/26
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant TrialBusiness Wire • 06/25/26
Natera Flashes A Buy Signal. Why Shares Just Leaped By Double Digits.Investors Business Daily • 06/24/26
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline UpdateBusiness Wire • 06/23/26
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant CongressBusiness Wire • 06/18/26
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/13/26
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRCZacks Investment Research • 06/08/26
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal CancerBusiness Wire • 06/04/26
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)The Motley Fool • 06/03/26
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of DirectorsBusiness Wire • 06/03/26
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma TrialZacks Investment Research • 06/01/26